Equities Analysts Offer Predictions for Bristol-Myers Squibb Company's FY2017 Earnings (BMY)

They now have $58.05 price objective on the biopharmaceutical company's stock. Out of 23 brokerage recommendations, 6 gave a Strong Buy, 4 issued a Buy, 11 issued Hold, 2 rated Under-perform and 0 issued a Sell. The company reported its last quarter on Dec 16. SunTrust Banks also issued estimates for Bristol-Myers Squibb Company's FY2018 earnings at $3.31 EPS, FY2019 earnings at $3.90 EPS, FY2020 earnings at $4.33 EPS and FY2021 earnings at $4.66 EPS.

A number of institutional investors have recently modified their holdings of the stock.

The Stock now has the market capitalization of $94.68 Billion, P/E (price to earnings ttm) of 21.29 and Weekly volatility of 2.71% and monthly volatility of 2.26% respectively. Bristol-Myers Squibb Company has a one year low of $49.03 and a one year high of $77.12. The growth estimate for the next quarter is 0 percent.

Bristol-Myers Squibb Company (NYSE:BMY) last issued its quarterly earnings data on Thursday, January 26th. The legal version of this piece can be read at https://baseballnewssource.com/markets/national-planning-corp-buys-6098-shares-of-bristol-myers-squibb-company-bmy/463934.html.

Effective implementation of the company's IO strategy is expected to be a key driver of its revenue growth in future years.

While looking at the Stock's Performance, Bristol-Myers Squibb Company now shows a Weekly Performance of 3.98%, where Monthly Performance is 13.91%, Quarterly performance is 0.46%, 6 Months performance is -2.36% and yearly performance percentage is -8.21%. The stock presently has a consensus rating of "Hold" and a consensus price target of $63.39.

On Monday Bristol-Myers Squibb Company (NYSE:BMY) share price closed at $56.56. AE Wealth Management LLC acquired a new stake in Bristol-Myers Squibb Company during the fourth quarter worth approximately $325,000. During the same quarter in the prior year, the company earned $0.38 earnings per share. The stock has a 50 day moving average of $53.07 and a 200 day moving average of $55.03. However, the company is confident in defending its second-line non-small cell lung cancer (or NSCLC) market share due to its solid clinical profile of IO drugs and its robust commercial infrastructure. Taking a look into the performance of BMY stock, investor will come to know that the weekly performance for this stock is valued at 3.52%, resulting in a performance for the month at 18.79%. Hilliard Lyons upgraded Bristol-Myers Squibb Company from a neutral rating to a buy rating and set a $69.00 price objective for the company in a research note on Friday, October 28th. The biopharmaceutical company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $0.67 by $0.04. In the past week, the company has outperformed the S&P 500 by 2.68% and the outperformance has advanced to 14.6% for the last 4 weeks period.

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 1st. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and worldwide copyright and trademark laws. Stockholders of record on Friday, January 6th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.76%. Launched in 2012 by Bristol-Myers Squibb, the II-ON was one of the first networks to bring academia and industry together to further the scientific understanding of I-O, and has expanded from 10 to 15 sites including more than 250 investigators working on over 150 projects across 20 tumor types. The ex-dividend date of this dividend is Wednesday, January 4th. Bristol-Myers Squibb Company has an average rating of Hold and an average price target of $61.90.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.

  • Zachary Reyes